David Epstein Acquires AgomAb Therapeutics Stock; Cantor Fitzgerald Initiates Coverage
What happened
Director David Epstein purchased 10,000 shares of AgomAb Therapeutics stock on October 21, 2026, at an average price of $8.88 per share, totaling $88,800.00. Following the purchase, his ownership increased to 25,000 shares. Separately, Cantor Fitzgerald began stock coverage on AgomAb Therapeutics. The company last reported earnings of ($0.46) EPS for the quarter on August 6th.
From dailypolitical.com
Why it matters
The acquisition by Director David Epstein was disclosed to the Securities & Exchange Commission. This insider activity, combined with new analyst coverage, may influence investor sentiment regarding AgomAb Therapeutics' valuation and future performance.
From dailypolitical.com
Who's involved
- Cantor FitzgeraldAmerican financial services company that initiated stock coverage on AgomAb Therapeutics.
- David EpsteinDirector of AgomAb Therapeutics who acquired 10,000 shares of the company's stock.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- David EpsteinSpeculative
David Epstein's increased ownership could affect his personal investment returns in AgomAb Therapeutics.
Keep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald issued a coverage report on AbCellera, a company whose shares trade on Nasdaq.
- Cantor Fitzgerald, Citigroup, and MarketBeat issued rating updates and price targets for Rigel Pharmaceuticals, Inc.
- Benzinga reported analyst research notes and Cantor Fitzgerald decreased its price objective for EMCOR Group, Inc.
- Cantor Fitzgerald upgraded BMNR shares to strong-buy on July 1, 2026.